Related Experiment Video
Updated: Aug 19, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
Diagnosis and case finding in familial hypercholesterolemia
1M.I. Bassett Research Institute, Cooperstown, New York 13326.
Insights
Heterozygous familial hypercholesterolemia (hFH) poses a high coronary disease risk. Current screening methods fail to identify most hFH cases, necessitating improved strategies and physician awareness.
Area of Science:
- Cardiology
- Genetics
- Public Health
Background:
- Heterozygous familial hypercholesterolemia (hFH) significantly elevates coronary disease risk.
- Despite its risks, hFH diagnosis and case finding face challenges.
Purpose of the Study:
- To evaluate if hFH meets World Health Organization criteria for screening.
- To identify barriers in current hFH screening strategies and propose solutions.
Main Methods:
- Review of existing hFH identification strategies.
- Analysis of barriers hindering screening implementation.
- Assessment of hFH against WHO screening criteria.
Main Results:
- hFH meets WHO criteria for a screening program.
- Current strategies (e.g., universal cholesterol testing, family screening, premature event screening) are largely unsuccessful in identifying hFH cases.
- Significant barriers exist for both patients and physicians in executing screening recommendations.
Conclusions:
- hFH warrants a dedicated screening approach due to its high cardiovascular risk.
- Existing screening strategies are insufficient for widespread hFH case detection.
- Overcoming barriers, including enhancing primary care provider awareness, is crucial for effective hFH identification.
Abstract:
Heterozygous familial hypercholesterolemia (hFH) is known to be associated with a high risk for development of coronary disease. However, several issues still remain as to whether this condition merits a special approach to diagnosis and case finding. It appears that hFH meets the World Health Organization criteria as a condition worthy of a screening program. However, none of several current strategies appears to be successful in the identification of even a majority of hFH cases. These strategies include community-wide programs to test everyone for total serum cholesterol levels, the testing of first degree family members of hFH patients or family members of patients with coronary disease at age < or = 55 years, or even the screening of patients with premature vascular events. The barriers for patients and physicians to carry out screening recommendations need to be identified and removed, including the need to sensitize primary care providers about the importance of identifying those with hFH.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Cholesterol: Significance and Regulation
Considering cholesterol and...
Pharmacogenomics: Identification of New Drug Targets
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Atherosclerosis III: Management

